Search hospitals > Massachusetts > Boston
Joslin Diabetes Center
Claim this profileBoston, Massachusetts 02215
Global Leader in Diabetes
Global Leader in Type 1 Diabetes
Conducts research for Type 2 Diabetes
Conducts research for Postprandial Metabolism
Conducts research for Retinopathies
169 reported clinical trials
16 medical researchers
Summary
Joslin Diabetes Center is a medical facility located in Boston, Massachusetts. This center is recognized for care of Diabetes, Type 1 Diabetes, Type 2 Diabetes, Postprandial Metabolism, Retinopathies and other specialties. Joslin Diabetes Center is involved with conducting 169 clinical trials across 101 conditions. There are 16 research doctors associated with this hospital, such as Osama Hamdy, Jason Gaglia, Dr., Mary E Patti, MD, and Lori Laffel.Area of expertise
1Diabetes
Global LeaderGAD65A positive
mIAA positive
IA-2A positive
2Type 1 Diabetes
Global LeaderGAD65A positive
mIAA positive
IA-2A positive
Top PIs
Osama HamdyJoslin Diabetes Center1 year of reported clinical research
Studies Diabetes
Studies Osteoarthritis
9 reported clinical trials
13 drugs studied
Jason Gaglia, Dr.Joslin Diabetes Center4 years of reported clinical research
Studies Type 1 Diabetes
Studies Diabetes
7 reported clinical trials
8 drugs studied
Mary E Patti, MDJoslin Diabetes Center5 years of reported clinical research
Studies Postprandial Metabolism
Studies Low Blood Sugar
6 reported clinical trials
14 drugs studied
Lori LaffelJoslin Diabetes Center2 years of reported clinical research
Studies Diabetes
Studies Type 1 Diabetes
6 reported clinical trials
11 drugs studied
Clinical Trials running at Joslin Diabetes Center
Diabetes
Type 1 Diabetes
Type 2 Diabetes
Postprandial Metabolism
Reactive Hypoglycemia
Low Blood Sugar
Contrast-induced Nephropathy
Cardiovascular Disease
Heart Failure
Diabetic Kidney Disease
Omnipod Systems
for Type 1 Diabetes
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 or type 2 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Period 1) then switch to the opposite system for the next 4 weeks (Period 2). Everyone will use the Omnipod 5 SmartAdjust 2.0 System for the last 4-6 weeks (Period 3). During Period 3, participants will have a goal of administering no more than 3 meal or snack boluses per day.
Recruiting1 award N/A4 criteria
Lifestyle Intervention
for Diabetes
This study is designed to evaluate whether epigenetic markers in overweight men with type 1 diabetes (T1D) or type 2 diabetes (T2D) can be improved with a 3 month lifestyle intervention or program focused in glycemic intervention.
Recruiting1 award N/A5 criteria
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Joslin Diabetes Center?
Joslin Diabetes Center is a medical facility located in Boston, Massachusetts. This center is recognized for care of Diabetes, Type 1 Diabetes, Type 2 Diabetes, Postprandial Metabolism, Retinopathies and other specialties. Joslin Diabetes Center is involved with conducting 169 clinical trials across 101 conditions. There are 16 research doctors associated with this hospital, such as Osama Hamdy, Jason Gaglia, Dr., Mary E Patti, MD, and Lori Laffel.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.